Sanofi

Why trials sponsored by Sanofi stopped, in this sample of ClinicalTrials.gov.

29 stopped trials with a clear reason; 86% ended for non-scientific reasons.

Trials

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
  NCT06444451 · TERMINATED · funding business
  “Sponsor decision; the decision is not related to any safety concern”
• Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
  NCT06118099 · TERMINATED · funding business
  “Sponsor decision; the decision is not related to any safety concern”
• A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
  NCT06028230 · TERMINATED · funding business
  “Sponsor decision. Not related to safety concern.”
• A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
  NCT05712278 · TERMINATED · funding business
  “Sponsor's decision”
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
  NCT04661033 · TERMINATED · funding business
  “Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.”
• Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
  NCT04659603 · TERMINATED · funding business
  “Sponsor decision, the decision is not related to any safety concern.”
• SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
  NCT04154956 · TERMINATED · funding business
  “Sponsor decision, the decision is not related to any safety concern.”
• Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
  NCT04191382 · TERMINATED · funding business
  “early discontinuation based on strategic sponsor decision not driven by any safety concerns”
• Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
  NCT04059484 · TERMINATED · funding business
  “Sponsor decision to prematurely stop the study, not linked to any safety concern.”
• A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
  NCT03236311 · TERMINATED · slow accrual
  “(Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.)”
• To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
  NCT02497612 · TERMINATED · futility
  “All treatment arms met the futility criteria for efficacy during the pre-planned interim analysis, therefore the study was stopped.”
• Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
  NCT01955629 · TERMINATED · safety
  “The study enrollment was prematurely halted due to safety reasons.”
• An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
  NCT01764997 · TERMINATED · slow accrual
  “Due to small number of participants entering randomization. Not a safety issue.”
• Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
  NCT01567904 · TERMINATED · regulatory
  “Decision from Sanofi to withdraw on a worldwide basis the Marketing Authorisation Applications for Semuloparin sodium in the adult indication”
• Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
  NCT01505062 · TERMINATED · funding business
  “Study stopped not for safety reasons. Due to review of clinical development plans and priorities, Sponsor decided to stop development of the product.”
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
  NCT01252355 · TERMINATED · funding business
  “Sponsor decision to prematurely stop the study, not linked to any safety concern.”
• Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
  NCT01217814 · TERMINATED · funding business
  “Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns”
• Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
  NCT01151137 · TERMINATED · safety
  “The study was stopped because of safety concerns”
• Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
  NCT01081938 · TERMINATED · slow accrual
  “Recruitment challenges”
• Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
  NCT01079364 · TERMINATED · slow accrual
  “Slow recruitment”
• Effect of Chronic Supplementation of L-arginine in the Muscular Performance
  NCT00785811 · TERMINATED · slow accrual
  “Required by the investigator. The site could not recruit patients anymore.”
• Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
  NCT00766688 · TERMINATED · futility
  “AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy”
• Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
  NCT00774878 · TERMINATED · funding business
  “Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy concerns”
• An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
  NCT00576667 · TERMINATED · regulatory
  “Company decision taken in light of demands by certain national health authorities”
• Rasburicase (Fasturtec) Registration Trial
  NCT00607152 · TERMINATED · slow accrual
  “the patient enrollment is too difficult”
• Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults
  NCT00344942 · TERMINATED · slow accrual
  “patient's recruitment too difficult”
• TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults
  NCT00315549 · TERMINATED · funding business
  “Pediatric development program terminated by sponsor”
• Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections
  NCT00174811 · TERMINATED · funding business
  “Pediatric development program terminated by sponsor”
• ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
  NCT00544180 · TERMINATED · regulatory
  “The trial was terminated due to lack of compliance with GCP regulations.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.